EUVIMEDEUVIMED entdecken
Übersichtsarbeit

STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact

Siobhán McGettigan, Denis Curtin, Denis O'Mahony

Expert Review of Clinical Pharmacology · 02.12.2023 · 16 (12) · 1175-1185

DOI: 10.1080/17512433.2023.2280219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 10.11.2023. Verfasst von Siobhán McGettigan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Potentially Inappropriate Medication List. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: STOPP/START criteria for potentially inappropriate medications (PIMs, STOPP) and potential prescribing omissions (PPOs, START) have gained considerable interest and traction since they were first published in 2008. This review focuses on their uptake and impact in various clinical settings. AREAS COVERED: STOPP/START criteria, now in their third iteration, are explicit criteria designed to facilitate detection of common and clinically important PIMs and PPOs during routine medication review in any clinical setting. We examine the influence of the criteria, particularly in clinical trials that focused on their impact on clinically relevant endpoints. EXPERT OPINION: STOPP/START criteria are widely used in several countries within Europe and beyond for medication review and audit. As a discreet intervention, the criteria have been tested in several single-center and two large-scale multi-center clinical trials. The single-center trials indicate that STOPP/START criteria reduce polypharmacy, inappropriate prescribing, ADRs (adverse drug reactions), medication cost and falls. In contrast, the SENATOR and OPERAM multicentre trials did not demonstrate significant reduction in ADRs, all-cause mortality, drug-related hospital readmissions, nor any improvement in quality-of-life. Further clinical trials are required to examine whether STOPP/START criteria as an intervention can deliver significant clinical benefit in a reproducible manner in various clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsPotentially Inappropriate Medication ListSystemic Inflammatory Response SyndromeCOVID-19EuropeHumansPolypharmacyInappropriate PrescribingAged

Stichwörter der Autor:innen

PolypharmacySTOPP/START criteriaadverse drug eventsdeprescribinginappropriate prescribingmedication reviewmultimorbidityolder people

Autor:innen und Institutionen

  • Department of Medicine, University College Cork, Cork, Ireland.
  • Department of Geriatric Medicine, Cork University Hospital, Wilton, Cork, Ireland.

Zitieren

APA

McGettigan, S., Curtin, D., & O'Mahony, D. (2023). STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact. Expert Review of Clinical Pharmacology, 16(12), 1175-1185. https://doi.org/10.1080/17512433.2023.2280219

Vancouver

McGettigan S, Curtin D, O'Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact. Expert Review of Clinical Pharmacology. 2023;16(12):1175-1185. doi:10.1080/17512433.2023.2280219

BibTeX
@article{McGettigan2023,
  author = {McGettigan, Siobhán and Curtin, Denis and O'Mahony, Denis},
  title = {STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  volume = {16},
  number = {12},
  pages = {1175--1185},
  doi = {10.1080/17512433.2023.2280219}
}
Kostenlos starten →